A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2400 participants.
Also called NCT02057302
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,400 participants
- Registry
-
NCT02057302
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02057302. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
- Condition
- Dyslipidemia
- Intervention (Drug)
- Xuezhikang capsule
- Lead sponsor
- China Academy of Chinese Medical Sciences
Record details
- Record id
cardio:ct-nct02057302- Content hash
7d700af19f7f3894c5686805f317d8c83c537ad6bf9402c4b18e378bed0ea9be